Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

fgggggggg Apr. 25 at 4:38 PM

$PHAT this

0 · Reply

fgggggggg Apr. 25 at 4:38 PM

$PHAT

0 · Reply

longshot45 Apr. 25 at 3:41 PM

$PHAT I’m still hoping they try to push this back down to 10 for the may options. I guess it will all come down to how much they can manipulate the narrative post ER and if they write a bunch of articles about outstanding debt and current EPS. But I do figure this will be the last time that will be possible

0 · Reply

longshot45 Apr. 24 at 7:47 PM

$PHAT When you all buy, do you set your price or just pay the ask? The MMs seem to love walking the price down to the bid, then reversing themselves. Not really sure what game they are playing when they do that though

1 · Reply

Morrito23 Apr. 24 at 4:01 PM

$PHAT Bought another whopping…100 shares. That script chart looks nice AND there was a pretty big (based on our average volume) block buy at 11:43 with 150k shares

0 · Reply

fgggggggg Apr. 24 at 3:43 PM

$PHAT More fake trading. It isnt even a frutiful exercise as it yield very few shares. Same boring playbook. BULLISH AF

0 · Reply

stocksUP59 Apr. 24 at 2:25 PM

$PHAT algos trying to control SP. HOLD STRONG. Scripts continue to climb. For the week ending 4/17/26, Voquezna normalized TRx were 15,125 (+6% wk/wk, +8% mo/mo). Non-normalized TRx were 12,732

1 · Reply

Randy_Lahey_Trevor_Corey Apr. 24 at 1:55 PM

$PHAT this price action is sketch

0 · Reply

fgggggggg Apr. 24 at 11:27 AM

$PHAT

0 · Reply

Withermania Apr. 23 at 7:44 PM

$PHAT hey chat - are we back?

0 · Reply

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 15, 2026, 1:30 PM EDT - 10 days ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 8:00 AM EDT - 19 days ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Mar 11, 2026, 3:30 PM EDT - 6 weeks ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 10:30 AM EST - 7 weeks ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 17, 2026, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 12, 2026, 11:30 AM EST - 2 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Jan 7, 2026, 10:33 PM EST - 3 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 3 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 3 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Dec 2, 2025, 3:25 PM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 9:30 AM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:40 PM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:00 PM EST - 5 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 6 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sep 8, 2025, 1:00 PM EDT - 8 months ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:10 AM EDT - 8 months ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 9 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 23, 2025, 4:15 PM EDT - 10 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 10 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 11, 2025, 10:40 AM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 12:27 PM EDT - 11 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 5, 2025, 9:55 AM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 11:30 AM EDT - 11 months ago

Phathom Pharmaceuticals Transcript: AGM 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 7, 2024, 1:30 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 6, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Nov 29, 2023, 4:15 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: 6th Annual ISI HealthCONx Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Nov 9, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Nov 2, 2023, 11:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: FDA Announcement

Nov 1, 2023, 5:00 PM EDT - 2 years ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Jun 14, 2023, 11:00 AM EDT - 3 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Oct 18, 2021, 8:30 AM EDT - 4 years ago

Phathom Pharmaceuticals Transcript: Study Result

May 21, 2021, 10:45 AM EDT - 5 years ago

Phathom Pharmaceuticals Transcript: AGM 2021

Apr 29, 2021, 4:30 PM EDT - 5 years ago

Phathom Pharmaceuticals Transcript: Study Result

Dec 14, 2020, 1:00 PM EST - 5 years ago

Phathom Pharmaceuticals Transcript: Investor Day 2020

May 21, 2020, 9:45 AM EDT - 6 years ago

Phathom Pharmaceuticals Transcript: AGM 2020

fgggggggg Apr. 25 at 4:38 PM

$PHAT this

0 · Reply

fgggggggg Apr. 25 at 4:38 PM

$PHAT

0 · Reply

longshot45 Apr. 25 at 3:41 PM

0 · Reply

longshot45 Apr. 24 at 7:47 PM

1 · Reply

Morrito23 Apr. 24 at 4:01 PM

$PHAT Bought another whopping…100 shares. That script chart looks nice AND there was a pretty big (based on our average volume) block buy at 11:43 with 150k shares

0 · Reply

fgggggggg Apr. 24 at 3:43 PM

$PHAT More fake trading. It isnt even a frutiful exercise as it yield very few shares. Same boring playbook. BULLISH AF

0 · Reply

stocksUP59 Apr. 24 at 2:25 PM

$PHAT algos trying to control SP. HOLD STRONG. Scripts continue to climb. For the week ending 4/17/26, Voquezna normalized TRx were 15,125 (+6% wk/wk, +8% mo/mo). Non-normalized TRx were 12,732

1 · Reply

Randy_Lahey_Trevor_Corey Apr. 24 at 1:55 PM

$PHAT this price action is sketch

0 · Reply

fgggggggg Apr. 24 at 11:27 AM

$PHAT

0 · Reply

Withermania Apr. 23 at 7:44 PM

$PHAT hey chat - are we back?

0 · Reply

fgggggggg Apr. 23 at 7:13 PM

$PHAT

0 · Reply

fgggggggg Apr. 23 at 11:01 AM

$PHAT

0 · Reply

Walleyeslayer Apr. 22 at 8:43 PM

$PHAT 8 days to ER....

0 · Reply

Canvasback33 Apr. 22 at 8:09 PM

$PHAT ??? What did I miss?

1 · Reply

Randy_Lahey_Trevor_Corey Apr. 22 at 8:01 PM

$PHAT head scratcher, can’t do many more of those days

0 · Reply

Ecryder Apr. 22 at 7:46 PM

$PHAT last Feb it peaked out around 13.56 and it turned downwards at 13.47ish now. My thought is thats it looking like a big seller?

0 · Reply

Randy_Lahey_Trevor_Corey Apr. 22 at 7:42 PM

$PHAT wow fuck take it down

0 · Reply

Walleyeslayer Apr. 22 at 6:51 PM

$PHAT wow. Shorts are 💪 today. They ran it 3 bucks and will crush it hoping weak hands sell them cheap shares. I have said it before and I’ll say it again. The volume on this ticker is just too low. Eventually, it will run.

0 · Reply

fgggggggg Apr. 22 at 6:39 PM

$PHAT fake trading because no one is selling. These moves absolutely do not yield them many shares. Thats why it is the same thing over and over

1 · Reply

Randy_Lahey_Trevor_Corey Apr. 22 at 6:39 PM

$PHAT shakeout before the breakout I guess

0 · Reply

StardustTrader Apr. 22 at 6:39 PM

$PHAT such low volume... The last time the daily 20 crossed above the daily 50 was june of last year, resulting in the increase from 5s to 20. Were at that point, starting in the 11s now. Easy 30s still on deck.

0 · Reply

TheFlyingDutchmann Apr. 22 at 6:30 PM

$PHAT loving this less on the other hand

2 · Reply

Market Cap	965.87M
Revenue (ttm)	175.11M
Net Income (ttm)	-221.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-126.35%
Debt to Equity Ratio	-0.48

Volume	1,485,400
Avg Vol	1,119,360
Day's Range	N/A - N/A
Shares Out	79.43M
Stochastic %K	15%
Beta	0.61
Analysts	Strong Sell
Price Target	$23.70